NeuBase Therapeutics selling stake in company to New York investment firm Alumni Capital


NeuBase specializes in genetic medicine therapies that target disease-triggering DNA and RNA mutations.

Previous Congressional investigation reveals 'atypical,' 'inappropriate' collaboration between FDA, Biogen
Next Here's what's next for Providence HQ in Renton after sale to Seattle Children's